Is hepatocellular carcinoma surveillance in high-risk populations effective?

IF 1.2 Q4 ONCOLOGY

Hepatic Oncology Pub Date : 2020-07-24 DOI:10.2217/hep-2020-0012

Kristeen Onyirioha, Sukul Mittal, Amit G Singal

引用次数: 0

Abstract

Several professional societies recommend hepatocellular carcinoma (HCC) surveillance in high-risk patients including patients with cirrhosis from any etiology and subsets of noncirrhotic chronic hepatitis B virus infection. The efficacy of HCC surveillance to increase early detection and improve survival has been demonstrated in a large randomized controlled trial among hepatitis B virus patients and several cohort studies among those with cirrhosis. However, the effectiveness on HCC surveillance, when applied in clinical practice, is lower due to low utilization of HCC surveillance among at-risk patients, poorer test performance given operator dependency and differences in patient characteristics, and downstream process failures such as treatment delays. Interventions to increase surveillance utilization and improve surveillance test performance should improve surveillance effectiveness in the future.

查看原文本刊更多论文

对高危人群进行肝细胞癌监测是否有效？

一些专业协会建议对高危患者进行肝细胞癌（HCC）监测，包括任何病因引起的肝硬化患者和非肝硬化慢性乙型肝炎病毒感染者。一项针对乙型肝炎病毒感染者的大型随机对照试验和几项针对肝硬化患者的队列研究都证明了 HCC 监测对提高早期发现率和改善生存率的功效。然而，由于高危患者对 HCC 监测的利用率较低、操作者的依赖性和患者特征的差异导致检测效果较差，以及治疗延误等下游流程失败，因此 HCC 监测在临床实践中的应用效果较低。提高监测利用率和改善监测检验性能的干预措施应能在未来提高监测效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hepatic Oncology ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.